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Background: As a public health emergency of international concern, the COVID-19
outbreak has had a tremendous impact on patients’ psychological health. However,
studies on psychological interventions in patients with COVID-19 are relatively rare.
Objectives: This study examined the effectiveness of Cognitive Behavioral Therapy
(CBT) in relieving patients’ psychological distress during the COVID-19 epidemic.
Methods: Ninety-three eligible participants selected by cluster sampling were
randomized to an intervention group (N = 47) and a control group (N = 46). Participants
in the control group received routine treatment according to the Chinese Management
Guidelines for COVID-19, while participants in the intervention group received routine
treatment with additional CBT. The Chinese Version of Depression Anxiety and Stress
Scale-21 (DASS-21) was used to evaluate depression, anxiety, and stress for all
participants at baseline and post-intervention. Two-sided t-test, and proportion tests
were used to examine the differences between the intervention and control group for each
DASS-21 indicator. Univariate linear regression was used to examine the association
between chronic disease status and change in each DASS-21 indicator after intervention.
Two-way scatter plots were generated to show the association of the length of hospital
stay and the changes of each DASS-21 indicator by intervention and control groups.
Results: Significant decreases in means were found for scales of depression, anxiety,
stress and total DASS-21 in both intervention (p < 0.001) and control group (p = 0.001),
with participants in the intervention group having a bigger reduction in means. After the
intervention, more participants in the intervention group had no depression or anxiety
symptoms than in the control group, but no statistical differences were found (p > 0.05).
Compared with participants with chronic disease, participants with no chronic disease
had a significantly larger reduction of total DASS-21 scale (coefficient = −4.74, 95% CI:
−9.31; −0.17).The length of hospital stay was significantly associated with a greater
increase in anxiety scale in the intervention group (p = 0.005), whilst no significant
association was found in the control group (p = 0.29).
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Conclusions: The patients with COVID-19 experienced high levels of anxiety,
depression and stress. Our study result highlights the effectiveness of CBT in improving
the psychological health among patients with COVID-19, also suggests that CBT should
be focused on patients with chronic disease and those who have longer hospital stays.
These results have important implications in clinical practice in improving psychological
health in the context of COVID-19 pandemic.
Trial Registration: ISRCTN68675756. Available at: http://www.isrctn.com/
ISRCTN68675756.
Keywords: cognitive behavioral therapy (CBT), COVID-19, DASS-21, psychological health, depression, anxiety,
stress
INTRODUCTION
Coronavirus disease-2019 (COVID-19) is a respiratory infectious
illness caused by a new virus. In 30 January 2020, The World
Health Organization declared the COVID-19 outbreak a public
health emergency of international concern (1). By 6 June 2020,
COVID-19 had affected more than 7 million people worldwide
in 213 countries, resulting in more than 400,857 deaths (2).
COVID-19 has resulted in a significant burden on health systems
as well economic development, along with a significant impact on
individual’s physical, and psychological health.
In China, during the initial stage of the COVID-19 outbreak,
the number of infected and confirmed cases increased rapidly
in a short period due to a lack of knowledge of this new
infectious disease. The data shows that on January 27, 2020,
there were 4,515 cases confirmed in mainland China, of which
76.0% were patients with mild symptoms (3). Later, with the
improvement of COVID-19 nucleic acid detection tests, the
number of diagnosed patients increased dramatically to 14,380
by February 1, 2020, and the proportion of patients with mild
symptoms increasing to 83.2% (4). Given the significant concerns
around the spread of COVID-19, many people were under
extreme psychological stress, with an increased risk of panic, fear,
anxiety and depression (5–8).
Current studies on the incidence of psychological distress in
patients with COVID-19 vary significantly depending on the
differences in study setting, location and sample size. Kong et al.
(9) investigated 144 patients in a Wuhan hospital using the
Hospital Anxiety and Depression Scale and found that 28.5–
34.7% of participants had symptoms of anxiety and depression,
of which more than half had moderate to severe symptoms of
anxiety or depression. Cheng et al. (10) used the Anxiety Self-
rating Scale to investigate 76 patients in a Hangzhou hospital
and found that the incidence of anxiety was 65.8%, of which
22.4% had moderate to severe anxiety symptoms. A cross-
sectional study (11) from a Wuhan hospital showed that among
60 participants, the incidence of anxiety, tension and depression
were 47.5, 64.3, and 27.1%, respectively. The main causes of
psychological stress that identified from previous studies include:
(1) it always takes a long time for the patients to be diagnosed
with COVID-19, (2) always received misleading information
from the media, friends or colleagues, such as wrong disease
statistics and disease management strategy, which may cause
confusion and panic (6, 12), (3) worried about the uncertainty
of the treatment effect (13), (4) side effects of treatment such
as insomnia and nausea that can aggravate mental distress,
(5) worried about the families be infected because of their
close contacts (14), and (6) the isolated medical environment
which patients have never been experienced in their life.
To help patients with COVID-19 release their psychological
stress, it is urgent to provide psychological intervention in the
clinical practice.
Previous studies have reported that during the early stage of
public health outbreak emergencies (e.g., SARS), people suffer
from anxiety, depression and psychotic symptoms, and these
may lead to extreme outcomes such as suicide (15, 16). The
existing research also highlights that patients with COVID-19
suffer high levels of anxiety, depression, loneliness, despair and
anger (17). Results from a meta-analysis (12) showed that the
percentage of anxiety and depression symptoms in patients with
COVID-19 was significantly higher than that of the public and
front-line medical staff. A small number of patients demonstrate
extreme psychological behaviors during COVID-19 pandemic,
such as blaming, abusing medical staff and tearing up protective
equipment, which exposed front-line medical staff to a higher
risk (18).
In addition, multiple studies have documented that without
timely psychological intervention and assistance, psychological
symptoms such as anxiety and depression can further develop
into severe mental disorders such as acute stress disorder (ASD)
and post-traumatic stress disorder (PTSD). The psychological
disorders on patients resulting from the COVID-19 outbreak
have been widely reported (9–12, 17, 19, 20). For example,
Wu et al. (19) used the post-traumatic stress disorder checklist
(PCL-5) to assess PTSD and found among 8 patients with
COVID-19 (2 confirmed cases and 6 suspected cases), one
confirmed case and one suspected case were diagnosed with
PTSD. One case study reported that 2 patients with COVID-
19 developed ASD during quarantine (20). These psychological
disorders impact on patients’ quality of life and further
increased the psychological and economic burden for their
family members (21–23). Therefore, effective psychological
intervention at the early stages of COVID-19 is important
for patients.
Cognitive behavioral therapy (CBT) as an evidence-based
psychotherapy has been widely used in the treatment and
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prevention of physical and psychological distress in both the
community (24, 25) and inpatients (26, 27). CBT is a series of
methods, including cognitive reconstruction, behavioral change
and social support, with aims to help individuals to identify
stress levels and modify negative cognitive beliefs and behaviors
(28), reduce or eliminate symptoms of psychological distress, and
further help individuals back to their normal life in terms of
psychological and social functions. Many randomized controlled
trials (RCT) have highlighted that participants who received
CBT had a significant reduction in anxiety and depression levels
improving their quality of life. It was found that even a short
program of CBT can improve patients’ psychological stress and
somatic symptoms such as insomnia (29). Results from a meta-
analysis has shown studies have reached a consents that CBT
is the most effective and economical psychotherapy to relieve
psychological distress and related physical symptoms, such as
insomnia and physical fatigue (30, 31).
Despite these widely reported studies on the psychological
health of patients with COVID-19, most studies are limited
to a cross-sectional design. In addition, to the best of our
knowledge, there is no study in China that has conducted an
RCT investigating a CBT intervention to patients with COVID-
19, with the aim of improving their psychological health. The
aim of this study was to apply CBT to patients with COVID-
19 and examine the effectiveness of CBT in relieving patients’
psychological distress during the COVID-19 epidemic.
METHODS
Study Design and Setting
This RCT was conducted in the First Affiliated Hospital of
BengbuMedical College located in Bengbu, Anhui Province. This
has been a designated COVID-19 treatment hospital throughout
the epidemic. The intervention was delivered by nurses who have
received professional training in CBT as well as having COVID-
19 prevention and treatment knowledge and treatment training.
Participants
All participants were collected using cluster sampling from
the First Affiliated Hospital of Bengbu Medical College. All
participants expressed their willingness to participate in the study
during the period from February 4 to March 3, 2020. The range
of hospital admission were from 7 to 29 days.
A total of 109 patients were included at the initial screening.
The inclusion criteria were: (1) positive for the COVID-19
by the real-time fluorescent reverse transcription polymerase
chain reaction (RT-PCR) test for the detection of nucleic
acid in respiratory specimens with throat swabs and sputum
specimens, (2) patients with COVID-19 who had mild symptoms
in line with the diagnostic criteria of the Chinese Management
Guidelines for COVID-19 (32), and (3) had good communication
and understanding of Chinese. The exclusion criteria were:
(1) previously diagnosed with depression and currently taking
medication, (2) had prior cognitive dysfunction and (3)
had experienced another major stressful event (e.g., divorce,
bereavement) in the past year.
Based on the exclusion criteria 15 patients were excluded.
The sample consists of 94 participants who were selected and
randomly divided into the intervention group (N = 47) and the
control group (N = 47) using a computerized random number
generator by a trial statistician who had no clinical involvement
in the project. Furthermore, participants who were transferred to
Intensive Care Unit (ICU) for further treatment were excluded
(N = 1, in the control group) as disease progression did not
permit participation in the entire study. Study participants in the
control group received routine treatment (32), while participants
in the intervention group received the routine treatment with
the additional of CBT. The final sample was made up of 93
participants, with 47 in the intervention group and 46 in the
control group. The study procedure is shown in Figure 1.
The sample size was consistent with Lancaster et al. (33) study
which suggested that 30 or more patients are enough for a pilot
study. This gives adequate power to detect a difference between
two groups. This study was approved by the Ethics Committee
of the First Affiliated Hospital of Bengbu Medical College. All
participants were informed of: (1) the purpose of the study, (2)
their ability to withdraw from the study at any time, and (3)
that the study findings would be written up as a peer-reviewed
publication. All participants provided signed informed consent
to participate in the study.
Measurements
The demographic characteristics of the participants were
surveyed with a questionnaire tomeasure depression, anxiety and
stress levels using the Chinese Version of Depression Anxiety
and Stress Scale-21 (DASS-21) (34, 35) at baseline and post-
intervention. Previous studies have applied the Chinese version
of DASS-21 to assess short and long-term psychological impacts
of public health emergencies on people, such as SARS (36). In our
study, the Chinese Version of DASS-21 was used to explore the
participant’ psychological health and to evaluate the effectiveness
of CBT.
DASS-21 (37) is an abbreviated version of DASS-42. It
contains three indicators, which are depression, anxiety and
stress. Each indicator consists of 7 items, with a total of 21 items.
Each item within the indicator was designed to measure the
extent to which individuals have been bothered over past week,
with a range of 0 to 3 (0 = “did not apply to me at all” to 3
= “apply to me very much, or most of the time”). Scores for
depression, anxiety and stress were multiplied by two to calculate
the final score according to the instructions of DASS-21 (37).
Total scores of each indicator were ranged from 0 to 42, with
higher scores indicating a higher-level psychological distress.
The depressive levels were defined as normal: 0–9, mild:
10–13, moderate: 14–20, severe: 21–27, and extremely severe:
>27. Anxiety levels were defined as normal: 0–7, mild: 8–9,
moderate: 10–14, severe: 15–19, and extremely severe: >19.
Stress levels were defined as normal: 0-14, mild: 15–18, moderate:
19–25, severe: 26–33, and extremely severe >33. The DASS-
21 has been widely established and used as reliable and valid
assessment tool to access psychological health in adults in
different countries (37–41).
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FIGURE 1 | Flow chart of the study procedure.
The Chinese Version of DASS-21 developed by Taouk et al.
in 2001 has been tested as a reliable and valid tool initially
in Hong Kong, China. It was first introduced and applied to
college students in mainland China in 2010 (42). In 2012, Wen
et al. (35) slightly modified the Chinese Version of DASS-21 to
make it more suitable for the Chinese culture and evaluated its
reliability and validity in adults aged 18 years and above. The
results indicated that the overall Cronbach’s alpha coefficient of
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DASS-21 was 0.912 and the re-test reliability was 0.751, which
showed that the Chinese Version of DASS-21 is a reliable and
valid instrument and suitable for use in Chinese adults.
Procedure
All participants were treated separately in a single isolation ward
and were asked to complete the demographic characteristics
questionnaire. The baseline assessment of depression, anxiety,
and stress levels using the Chinese Version of DASS-21 were
conducted within 24 h of hospital admission.
Participants in the control group received routine treatment
(including antiviral treatment, symptomatic treatment of fever,
and nursing care) according to the Chinese management
guideline for COVID-19 (32). Participants in the intervention
group received routine treatment with the addition of CBT
including cognitive and behavior interventions.
The CBT has been described in detail in our previous study,
mainly including cognitive intervention, relaxation techniques
training, problem-solving training, and obtained a social support
strategy for participants (43). The cognitive intervention aimed
to help patients to correct their previous misconceptions in
regard to COVID-19 information and management strategies.
These included: (1) providing information that related to
knowledge of COVID-19, real-time information of the COVID-
19 outbreak such as number of patients who had been
discharged or cured, and (2) giving clear and comprehensive
explanations to patients’ questions. The behavior intervention
aimed to provide information on appropriate behaviors which
help patients in coping with the COVID-19 pandemic. These
included: (1) instruction on self-protection behaviors such as
proper hand-washing technique, (2) self-monitoring COVID-19
related symptom such as fever and dry cough, (3) relaxation
techniques such as music therapy and breath relaxation, (4)
encourage patients to maintain close communication with family
and friends through mobile phone orWeChat (a communication
app). These information and intervention have been provided to
patients in the intervention group. Participants were also asked
to record their feelings and their medical adherence every day.
The CBT intervention was performed once a day in the
morning, taking 30min to complete and was recorded by the
nurses. Each intervention was strictly carried out through face-
to-face communication, with a patient centered approachh so the
intervention could be adjusted based on the individual’s needs.
For example, the correct breathing relaxation methods, music
choosing, and self-monitoring of chronic diseases strategy were
instructed tomeet personal preference. All the interveners strictly
followed the required procedures according to the Technical
Guidelines (44) to prevent them to be infected with COVID-19.
Statistical Analysis
All data were entered at Excel then converted via Stat/Transfer
to STATA/SE 14 (StataCorp, USA) for analysis. The level of
statistically significance was set at P < 0.05.
Mean and standard deviation (SD) were presented for the
continuous variables of age, length of hospital stays, scales of
depression, anxiety, stress, and DASS-21 in the intervention and
control groups at baseline. N (%) were presented for participants
characteristics and categorial variables of different levels of
depression, anxiety, stress, and DASS-21 in the intervention and
control group at baseline. Analysis of variance (ANOVA) was
used to compare the mean differences of continuous variables
between intervention and control group at baseline. Chi-square
tests were used to examine the statistical differences between
intervention and control group by categorial variables at baseline.
The mean differences of continuous variables of DASS-
21 indicators between baseline and post-intervention were
examined by two-sided t-test for intervention and control
group. The proportion differences of categorical variable of
different levels DASS-21 indicators between baseline and
post-intervention were examined by the proportion tests for
intervention and control group.
The proportion differences between intervention and control
group for each level of DASS-21 indicators were examined by
proportion tests at baseline and post-intervention, respectively.
We further calculated the changes of each DASS-21 indicator
based on scores at two time-points, i.e., at baseline and post-
intervention. Univariate linear regression was used to examine
the association between chronic disease and changes of each
DASS-21 indicator. Two-way scatter plots were generated to
show the association of the length of hospital stay and the changes
of each DASS-21 indicator by intervention and control groups.
RESULTS
Of a total of 93 participants, 35.5% were men and 64.5%
were women. Average age was 48 years and mean length of
hospital stay was 14.4 days. The majority of participants were
married and had education level of secondary-graduate or below.
Approximately half of participants were retired or unemployed,
and 20.4% of them had chronic disease. At baseline, 50 (53.8%)
participants had depression symptoms (mild: 34.4%, moderate:
18.3%, severe: 1.10% and extremely severe: 0%); 84 (90.3%)
participants had anxiety symptoms (mild: 0%, moderate: 17.2%,
severe: 40.8% and extremely severe: 32.3%) and 68 (73.1%)
participants had stress symptoms (mild: 43.0%, moderate: 23.7%,
severe: 6.40% and extremely severe: 0%).
Participants characteristics and each DASS-21 indicator
(depression, anxiety and stress) by intervention and control
group at baseline are shown in Table 1. There were no significant
differences found between intervention and control group
by participants characteristics and each DASS-21 indicator at
baseline (p > 0.05).
Each DASS-21 indicator at baseline and post-intervention
by intervention and control group are shown in Table 2.
A significant decrease in means for scales of depression,
anxiety, stress and total DASS-21 were found in both
intervention (p < 0.001) and control groups (p = 0.001).
Participants in the intervention group had a bigger
deduction on means for scales of depression, anxiety, and
total DASS-21.
Significant increases in percentage of participants who had
no depression symptom was observed in the intervention group
(p < 0.001) and in the control group (p = 0.03). Significant
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TABLE 1 | Participants characteristics and DASS-21 indicators by intervention
and control group at baseline.
Characteristics Intervention group Control group P-value*
(N = 47) (N = 46)
Age (years, SD) 48.3 (12.2) 47.1 (10.6) 0.61
Length of hospital stay
(days, SD)
14.3 (4.87) 14.3 (3.94) 0.92
Gender (n, %)
Male 13 (27.7) 20 (43.5) 0.11
Female 34 (72.3) 26 (56.5)
Employment (n, %)
Employed 27 (57.5) 25 (54.4) 0.76
Unemployed/Retired 20 (43.5) 21 (45.7)
Education level (n, %)
Secondary and below 32 (68.1) 29 (63.0) 0.61
Tertiary 15 (31.9) 17 (37.0)
Marital Status (n, %)
Single 3 (6.38) 3 (6.52) 0.95
Married 39 (83.0) 39 (84.8)
Divorce or others 5 (10.6) 4 (8.70)
Chronic disease status (n, %)
Have chronic disease 11 (23.4) 8 (17.4) 0.47
No chronic disease 36 (76.6) 38 (82.6)
Depression scale (mean,
SD)
11.0 (3.30) 10.1 (3.17) 0.15
Anxiety scale (mean, SD) 17.1 (4.44) 16.5 (4.81) 0.51
Stress scale (mean, SD) 16.8 (3.59) 17.1 (3.71) 0.74
Total DASS-21 (mean, SD) 45.0 (8.50) 43.7 (8.83) 0.46
Depression level (n, %)
Normal 19 (40.4) 24 (52.2) 0.55
Mild 18 (38.3) 14 (30.4)
Moderate 9 (19.2) 8 (17.4)
Severe 1 (2.13) 0
Extremely severe 0 0
Anxiety level (n, %)
Normal 4 (8.50) 5 (10.9) 0.35
Mild 0 0
Moderate 5 (10.6) 11 (23.9)
Severe 21 (44.7) 17 (37.0)
Extremely severe 17 (36.2) 13 (28.3)
Stress level (n, %)
Normal 13 (27.7) 12 (26.1) 0.99
Mild 20 (43.6) 20 (43.5)
Moderate 11 (23.4) 11 (23.9)
Severe 3 (6.38) 3 (6.52)
Extremely severe 0 0
*Analysis of variance (ANOVA) was used to compare the mean differences of age, length
of hospital stay, scales of depression, anxiety, stress and DASS-21 between intervention
and control group.
Chi-square test were used to compare the statistical differences between intervention and
control group by participants characteristics, and the levels of depression, anxiety, stress,
and DASS-21.
decrease in percentage of participants who had mild (p = 0.04)
and moderate (p = 0.007) depression symptom were observed
in the intervention group, while only a significant decrease in











11.0 (3.30) 7.98 (2.42) −3.06 (3.68) <0.001
Anxiety scale (mean, SD)* 17.1 (4.44) 10.3 (3.70) −6.81 (5.16) <0.001
Stress scale (mean, SD)* 16.8 (3.59) 13.1 (3.44) −3.72 (3.52) <0.001
Total DASS-21 (mean,
SD)*
45.0 (8.50) 31.4 (7.42) −13.6 (8.53) <0.001
Depression level (n, %)#
Normal 19 (40.4) 37 (78.7) +18 (+38.3) <0.001
Mild 18 (38.3) 9 (19.2) −9 (−19.1) 0.04
Moderate 9 (19.2) 1 (2.13) −8 (−17.1) 0.007
Severe 1 (2.13) 0 −1 (−2.13) 0.31
Extremely severe 0 0 0 –
Anxiety level (n, %)#
Normal 4 (8.50) 22 (46.8) +18 (+38.3) <0.001
Mild 0 1 (2.13) +1 (+2.13) 0.31
Moderate 5 (10.6) 17 (36.2) +12 (+25.6) 0.004
Severe 21 (44.7) 7 (14.9) −14 (−29.8) 0.002
Extremely severe 17 (36.2) 0 −17 (−36.2) <0.001
Stress level (n, %)#
Normal 13 (27.7) 29 (61.7) +13 (+34.0) <0.001
Mild 20 (43.6) 15 (31.9) −4 (−11.7) 0.29
Moderate 11 (23.4) 2 (4.26) −9 (−19.1) 0.007
Severe 3 (6.38) 1 (2.13) −2 (−4.25) 0.31




10.1 (3.17) 8.07 (2.06) −2.00 (3.84) 0.001
Anxiety scale (mean, SD)* 16.5 (4.81) 11.2 (3.67) −5.33 (4.91) <0.001
Stress scale (mean, SD)* 17.1 (3.71) 12.8 (2.47) −4.28 (4.20) <0.001
Total DASS-21 (mean,
SD)*
43.7 (8.83) 32.0 (6.45) −11.6 (6.95) <0.001
Depression level (n, %)#
Normal 24 (52.2) 34 (73.9) +10 (+21.7) 0.03
Mild 14 (30.4) 12 (26.1) −2 (−4.3) 0.64
Moderate 8 (17.4) 0 −8 (−17.4) 0.003
Severe 0 0 0 –
Extremely severe 0 0 0 –
Anxiety level (n, %)#
Normal 5 (10.9) 13 (28.3) +8 (+17.4) 0.04
Mild 0 4 (8.70) +4 (+8.70) 0.04
Moderate 11 (23.9) 21 (45.7) +10 (+21.8) 0.04
Severe 17 (37.0) 8 (17.4) −9 (−19.6) 0.03
Extremely severe 13 (28.3) 0 −13 (−28.3) 0.001
Stress level (n, %)#
Normal 12 (26.1) 33 (71.7) +11 (45.6) <0.001
Mild 20 (43.5) 12 (26.1) −8 (−17.4) 0.08
Moderate 11 (23.9) 1 (2.17) −10 (−21.7) 0.002
Severe 3 (6.52) 0 −3 (−6.52) 0.08
Extremely severe 0 0 0 –
*The mean differences between baseline and after intervention were examined by two-
sided t-test.
#The proportion differences between baseline and after intervention were examined by
proportion tests for intervention and control group.
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FIGURE 2 | The percentage of each level of DASS-21 indicators by intervention and control group at baseline and post-intervention. (A) Depression level. (B) Anxiety
level. (C) Stress level.
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percentage of participants who had moderate symptoms was
found in the control group (p= 0.003).
In terms of anxiety, significant increases in the percentage of
participants who had no anxiety symptom (p < 0.001) and had
moderate anxiety symptoms (p = 0.004) were observed in the
intervention group, whilst a significant increase in the percentage
of participants who had no anxiety symptoms (p = 0.04), had
mild (p = 0.04) and moderate (p = 0.04) anxiety symptoms
were observed in the control group. A significant decrease in
percentage of participants who had severe and extremely severe
symptom was observed in both intervention and control groups
(p < 0.05).
Significant increases in the percentage of participants who had
no stress symptomwas observed in both intervention and control
groups (p< 0.001), whilst a significant decrease in the percentage
of participants who had moderate stress symptoms was observed
in both intervention and control groups (p = 0.007 and p =
0.002, respectively).
The percentage of each level of DASS-21 scale by intervention
and control group at baseline and after intervention are
shown in Figure 2. Overall, after intervention, all participants
progressed toward a better depression, anxiety and stress status
in both intervention and control groups. More participants
had no depression and anxiety symptom in the intervention
group than the control group, but no significant differences
were found.
After intervention, less participants had moderate depression
symptom, and no one had severe or extremely severe depression
symptoms compared to baseline, meanwhile more participants
have no depression symptoms in the intervention than the
control group, but no statistical difference was observed (p =
0.59) (Figure 2A). Compared to baseline, less participants had
severe anxiety symptoms, and no one had extremely severe
anxiety symptoms after intervention. More participants have no
anxiety symptoms in the intervention group than control group,
but no statistical difference was observed (p= 0.06) (Figure 2B).
After intervention, less participants had moderate and severe
stress symptoms compared to baseline. Slightly less participants
had no stress symptoms in the intervention group than control
group, while a higher number of participants in the intervention
than control group had mild stress symptoms. However, no
statistical differences were observed (Figure 2C).
We further found significant associations between chronic
disease status and changes in DASS-21 indicators (i.e., before and
post-intervention) (Table 3). Compared with participants who
had chronic disease, participants with no chronic disease had a
bigger reduction across all DASS-21 indicators, with significant
reductions found for total DASS-21 scale (coefficient = −4.74,
95% CI:−9.31;−0.17).
The associations were also found between the length of
hospital stay and changes of each DASS-21 indicator by
intervention and control group (Figure 3). The length of hospital
stay was significantly associated with a greater increase in anxiety
scale in the intervention group (p = 0.005), but no significant
association was found in the control group (p = 0.29). This
indicated that participants who had a longer hospital stay were
associated with less reduction of anxiety level after intervention.
TABLE 3 | The association between chronic disease status and changes of
DASS-21 indicators.
Chronic disease status Coefficient (95% CI) P-value
Changes of depression scale
Have chronic disease 0 (reference)
No chronic disease −1.87 (−3.77, 0.04) 0.05
Changes of anxiety scale
Have chronic disease 0 (reference)
No chronic disease −1.29 (−3.87, 1.30) 0.33
Changes of stress scale
Have chronic disease 0 (reference)
No chronic disease −1.59 (−3.54, 0.37) 0.11
Changes of DASS-21 scale changes
Have chronic disease 0 (reference)
No chronic disease −4.74 (−9.31, −0.17) 0.04
No significant associations were found between length of hospital
stay and scales of depression (intervention group, p = 0.39;
control group, p = 0.97), stress (intervention group, p = 0.32;
control group, p = 0.49) and DASS-21 (intervention group, p =
0.11; control group, p= 0.81).
DISCUSSION
Our findings suggest that patients with COVID-19 experienced
high levels of anxiety, depression and stress, which is consistent
with previous studies (9–12, 17). To our best knowledge, our
study is the first RCT to evaluate the effectiveness of CBT in
reducing depression, anxiety and stress levels for patients with
COVID-19 in China. Our results highlight the effectiveness of
CBT intervention in improving psychological health for patients
with COVID-19.
Our results indicate that the mean values of depression,
anxiety, stress and total DASS-21 decreased significantly in both
intervention and control groups after intervention. However,
patients in the intervention group had a bigger mean deduction
for scales of depression, anxiety and total DASS-21, indicating
that CBT can effectively improve the psychological health of
patients with COVID-19. These results are in line with previous
studies (7, 45). Many studies have indicated that CBT is the
most effective psychotherapy in reducing depression, anxiety
and stress symptom that has been recommended as a first-
line treatment for patients with psychological health disorders
(31, 46, 47). Besides, the benefit of CBT is also shown in
reducing insomnia and physical fatigue, which can further
improve patients’ quality of life (48, 49). Results from a number
of systematic reviews and meta-analyses (50–52) have also found
the effectiveness of CBT in improving short-term symptoms of
depression, anxiety and related disorders and further reducing
the risk of PTSD and social anxiety disorder.
Our results show more participants have no depression
and anxiety symptoms in the intervention group than the
control group although there were no statistical difference.
These results are comparable to previous research findings. For
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FIGURE 3 | The association between the length of hospital stay and changes of DASS-21 indicators by intervention and control group. (A) Depression. (B) Anxiety.
(C) Stress. (D) DASS-21.
example, Gromisch et al. (49) performed an RCT to evaluate
the effectiveness of CBT in pain and depression and found that
although there were no statistical significant difference between
intervention and control groups for symptoms of pain and
depression, an overall pain relief and improvement of depression
symptom was observed in the intervention group.
As found in previous studies (7, 45, 53), we assumed
that the main reason for the improvement of psychological
health of patients after CBT intervention is because they
received sufficient accurate information during the COVID-19
epidemic, along with timely clinical treatment, and were able to
self-monitor their own health status. These all may contribute
to the cognitive reconstruction process for patients, in which
dysfunctional thinking patterns are constantly corrected, leading
to the enhancement of self-confidence and self-efficacy, so as
to reduce psychological suffering (54). Behavior interventions,
including self-protection skills such as hand-washing technique,
self-monitoring strategies and relaxation techniques such as
music therapy, breathing relaxation, may also play an important
role in effectively reducing patients’ anxiety, depression and stress
symptoms. Previous studies (55, 56) suggested that listening
to pleasurable music can improve emotional self-regulation,
executive function and cognition. Emotion processing within
cortical and subcortical regions can be activated, which will
increase the secretion of neurotransmitter dopamine, reduce
the secretion of cortisol and further relieve stress and stress-
related health issues (55–57). Studies have shown that breathing
relaxation training leads to an overall reduction in sympathetic
tone and an increase in parasympathetic output which combats
increased sympathetic activities during stress (58, 59). This will
contribute to a reduction of negative emotions such as stress,
depression and anxiety (60–62).
We believe that patients who had close communication with
family and friends and receive encouragement frommedical staff
helps them improve their psychological health. Previous studies
have indicated that these strategies can enhance patient’s self-
confidence and reduce the psychological stress response caused
by epidemics such as SARS and COVID-19. It can further have a
great impact in promoting the physical and psychological health
of patients (9, 53, 63, 64).
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During the intervention, we found that by providing sufficient
accurate information regarding COVID-19 management,
patients’ negative emotions have been significantly improved. In
addition, we found that by improving of COVID-19 diagnosis,
treatment procedure, (65), and implementing policies (e.g.,
free treatment for patients, timely nucleic acid testing and
effective isolation and protection of family members), the
psychological stress have been significantly relieved among
patients with COVID-19.
Our results indicate that patients with chronic disease are
not as able to improve their psychological health than patients
without chronic disease. This implies that patients with chronic
disease who receive CBTmay not be able to significantly improve
their psychological health in a relatively short time. In our study,
20.4% of patients with COVID-19 had a history of cardiovascular
disease (CVD) or diabetes. Real-time data show severe COVID-
19 disease and death are often associated with CVD and diabetes
(14, 66). In addition, previous studies have widely reported that
the symptoms of anxiety and depression in patients with CVD
and diabetes are common and persistent (67, 68). This implies
that the CBT intervention needs to be particularly focused in
patients with chronic disease.
Our results also show that the patients with COVID-19 who
have longer hospital stays are less likely improve their anxiety
level in the intervention group. Patients who had longer hospital
stay are patients with comorbidities requiring longer and more
complex treatment. This can also lead to excessive worry and
fear further aggravating psychological stress for patients and
their family members. Therefore, our results find that CBT
interventions need to be focused on patients who have a long
duration of hospitalization.
STRENGTH AND LIMITATIONS
To the best of our best knowledge, this is the first RCT study
to evaluate the effectiveness of CBT in improving psychological
health for patients with COVID-19 by using a rigorous study
design andmethodology, which is themain strength of this study.
Secondly, all participants (except one patient who transferred to
ICU) completed the entire study, which ensured data integrity.
Thirdly, all health professionals and researchers who delivered
the CBT received special professional training followed by
a strict protocol, with the whole CBT intervention process
guided and supervised by a psychological specialist. However,
there are some limitations need to be recognized. A major
limitation is the intervention period is relatively short, with
a lack of long-term follow-up of participants after discharge.
This may lead to a failure to fully understand and explain
the impact of a CBT intervention. Secondly, there was a
relatively small number of participants. However, during the
COVID-19 outbreak, the traditional face-to-face CBT was
almost impossible for a large number of patients due to
the shortage of professionals and the rapid transmission of
the virus.
CONCLUSION
In conclusion, our study examined the effectiveness of CBT
to improve psychological health including depression, anxiety,
and stress in patients with COVID-19. Our results highlighted
that CBT can effectively improve the psychological health of
patients with COVID-19. Our results demonstrate that the
CBT intervention needs to be particularly focused on patients
with COVID-19 who have a chronic disease history and a
longer hospitalization.
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